{"id":87812,"identifier":"c26082c0585b70ad3bf4ebac3e0b6e9f919f1b9b1322d756a0057e7caa07f81a","request_date":"2019-07-02 15:18:22","date":"2019-06-06 14:00:00","duration_minutes":null,"publish_date":"2019-07-02 22:14:16","published_by":null,"status":"PUBLICADA","summary":"En el encuentro los representantes de la firma Novartis - AveXis, presentaron ante autoridades de la Secretaria de Coberturas y Recursos de Salud a ZOLGENSMA, un medicamento evaluado por FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE.UU) y EMA (Agencia Europea de Medicamentos), indicada para el tratamiento de la AME (atrofia medular espinal tipo I). \nSe trata de una terapia g\u00e9nica que a\u00fan no fue presentada en Argentina, ni aprobada por la ANMAT, por dicho motivo no tiene fijado un precio exacto, pero su valor se sit\u00faa en 2,1 millones de d\u00f3lares. En teor\u00eda la droga tiene acci\u00f3n curativa sobre la enfermedad.  A su vez se comentaron modelos de financiaci\u00f3n de la Droga.","motif":"Novartis AG adquiri\u00f3 Avexis (empresa l\u00edder en Cell & Gene Therapies ), el motivo de la reuni\u00f3n es la presentaci\u00f3n de  nuevos tipos de terapias g\u00e9nicas y avances tecnol\u00f3gicos para su desempe\u00f1o .","interest_type":"DIFUSO","place":"SECRETARIA DE COBERTURAS Y RECURSOS DE SALUD ,MINISTERIO DE SALUD Y DESARROLLO SOCIAL DE LA NACI\u00d3N","address":"LIMA 340,CABA","type":"PRESENCIAL","obligee_id":71806,"applicant_id":88488,"author_id":3586,"dependency_id":2814,"has_participants":true,"document_reference":null,"active":true,"deleted_by":null,"deleted_reason":null,"created_at":"2019-07-02 15:18:22","updated_at":"2019-07-02 22:14:16","deleted_at":null,"participants_count":9,"local_date":"2019-06-06","local_time":"14:00","obligee":{"id":71806,"dependency_id":2814,"dependency_name":"Secretar\u00eda de Coberturas y Recursos de Salud, Secretar\u00eda de Gobierno de Salud, Ministerio de Salud y Desarrollo Social","active":false,"position":"Secretario","created_at":"2018-09-18T16:05:33.000000Z","updated_at":"2019-12-13T21:42:47.000000Z","deleted_at":null,"person":{"id":179826,"name":"Gimenez, Luis Alberto","country":"Argentina","document":"10767679","email":null,"telephone":null,"gender":null},"dependency":{"id":2814,"name":"Secretar\u00eda de Coberturas y Recursos de Salud"}},"dependency":{"id":2814,"name":"Secretar\u00eda de Coberturas y Recursos de Salud"},"applicant":{"id":88488,"audience_id":87812,"email":null,"telephone":null,"occupation":"Gerente de Farmapolitica y Asuntos P\u00fablicos Novartis Argentina S.A","present":true,"absent":false,"applicant_type":"ARGENTINO","applicant_country":null,"representation_type":"REPRESENTACION","represented_entity":{"entity_type":"legal_entity","entity_id":437,"entity_name":"NOVARTIS ARGENTINA","cuit":"30516620397"},"interest_type":null,"active":true,"created_at":"2019-07-02T18:18:22.000000Z","updated_at":"2019-07-02T18:19:45.000000Z","deleted_at":null,"person":{"id":187115,"name":"Rodriguez Victor Pedro","country":"Argentina","document":"12324616","email":null,"telephone":null,"gender":null}},"participants":[{"id":100897,"audience_id":87812,"occupation":"Directora de la ANLIS","present":true,"created_at":"2019-07-02T19:50:29.000000Z","updated_at":"2019-07-02T19:50:29.000000Z","person":{"id":178133,"name":"Perandones, Claudia","country":"Argentina","document":"18534560","email":null,"telephone":null,"gender":null}},{"id":100898,"audience_id":87812,"occupation":"Subsecretaria de Programaci\u00f3n t\u00e9cnica y logistica","present":true,"created_at":"2019-07-02T19:53:55.000000Z","updated_at":"2019-07-02T19:53:55.000000Z","person":{"id":179254,"name":"Havela, Aixa Maisa Alina","country":"Argentina","document":"25672954","email":null,"telephone":null,"gender":null}},{"id":100899,"audience_id":87812,"occupation":"Directora de Asuntos Cientificos Novartis","present":true,"created_at":"2019-07-02T19:59:48.000000Z","updated_at":"2019-07-02T19:59:48.000000Z","person":{"id":187116,"name":"Ruiz Villamil Agustina","country":"Argentina","document":"27226939","email":null,"telephone":null,"gender":null}},{"id":100900,"audience_id":87812,"occupation":"Director de Acceso Novartis","present":true,"created_at":"2019-07-02T20:03:57.000000Z","updated_at":"2019-07-02T20:03:57.000000Z","person":{"id":180106,"name":"Ruival Daniel Francisco","country":"Argentina","document":"24227166","email":null,"telephone":null,"gender":null}},{"id":100901,"audience_id":87812,"occupation":"Head de Regulatorio Novartis","present":true,"created_at":"2019-07-02T20:04:55.000000Z","updated_at":"2019-07-02T20:04:55.000000Z","person":{"id":132375,"name":"Imirtzian Sergio","country":"Argentina","document":"17605803","email":null,"telephone":null,"gender":null}},{"id":100902,"audience_id":87812,"occupation":"HEOR Sr Managerr Novartis","present":true,"created_at":"2019-07-02T20:06:26.000000Z","updated_at":"2019-07-02T20:06:26.000000Z","person":{"id":187118,"name":"Peirano Vejo Isabel Letizia","country":"Argentina","document":"30814929","email":null,"telephone":null,"gender":null}},{"id":100904,"audience_id":87812,"occupation":"VP, Global Market Access Avexis","present":true,"created_at":"2019-07-02T20:19:08.000000Z","updated_at":"2019-07-02T20:20:51.000000Z","person":{"id":187615,"name":"Jose F. Gomez","country":"Estados Unidos de Am\u00e9rica","document":"505497590","email":null,"telephone":null,"gender":null}},{"id":100906,"audience_id":87812,"occupation":"Directora M\u00e9dica Espa\u00f1a Avexis","present":true,"created_at":"2019-07-02T20:40:06.000000Z","updated_at":"2019-07-02T20:40:06.000000Z","person":{"id":187616,"name":"Carmen Ruiz Thous","country":"Espa\u00f1a","document":"AAG59838","email":null,"telephone":null,"gender":null}},{"id":100914,"audience_id":87812,"occupation":"Sr. Marketing Director , Latin America & C\u00e1nada Avexis","present":true,"created_at":"2019-07-02T21:07:17.000000Z","updated_at":"2019-07-02T21:07:17.000000Z","person":{"id":187625,"name":"Everson G. Message","country":"Canad\u00e1","document":"YC924187","email":null,"telephone":null,"gender":null}}],"files":[]}